Clinigence and Spring Medical Systems Announce PQRS Reporting Partnership

ATLANTA-- Clinigence, a next-generation clinical business intelligence technology provider, today announced it will offer Physician Quality Reporting System (PQRS) reporting capabilities to users of Spring Medical Systems’ SpringCharts electronic health record (EHR) system. This new capability is an extension of the current alliance between the vendors, which provides Clinigence’s clinical reports to SpringCharts EHR users.

Clinigence, a 2013 PQRS Qualified EHR Data Submission Vendor, will automate the PQRS reporting process by integrating its software solution with SpringCharts EHR to extract and analyze data on a daily basis. Through an online dashboard, providers can access reports which provide details about federally-defined quality metrics. Providers can then proactively address care gaps before Clinigence automatically submits reports to Medicare. The PQRS program is currently awarding incentive payments to participating practices.

“PQRS is one of the programs that encourages early adoption by providing incentive payments and then having penalties for non-compliance later on,” said Kobi Margolin, CEO of Clinigence. “Given the current squeeze on providers’ revenue, we want to help them take advantage of any opportunity that will provide more revenue. By connecting directly to their EHR platform, we are confident our solution will help practices earn the bonus now and avoid financial downfalls in the coming years.”

The Clinigence solution is built around several key capabilities, including clinical data analytics, data mining, predictive modeling and business intelligence. Leveraging cloud-based semantic collaboration, the solution fuels a continuous cycle of improvement in staff performance and process effectiveness while accelerating the creation of best practices.

“Practices around the nation are inundated with so many compliance and regulatory reporting requirements and changes, that it can be difficult to keep it all straight,” said Mark Benvegnu, CEO of Spring Medical Systems. “Our top priority is to make it easy on our clients by automating and streamlining the new processes for them. The capabilities Clinigence will provide for PQRS reporting will take pressure off of providers so they can rest assured their reporting is done completely and accurately and they can focus on other challenges.”

About Spring Medical Systems

Spring Medical Systems, Inc., was founded by a team of physicians and technology professionals with the primary goal of developing easy-to-use software solutions that empower physicians to increase efficiency, reduce costs, and provide better patient care. The Company’s flagship offering is the SpringCharts® family of products. These innovative solutions combine the right mix of rich functionality, intuitive ease of use, and affordability needed to enable rapid and complete documentation with a minimum of cost and disruption. Now in use by thousands of physicians in a variety of medical specialties, SpringCharts products provide complete solutions for independent medical offices.

About Clinigence

Clinigence, LLC, in Atlanta, GA, is a health information technology company that develops, publishes and delivers collaborative software-as-a-service (SaaS) to help healthcare providers derive business value from clinical data and quality patient care. The Clinigence solution is tailored to the emerging needs of healthcare providers due to the shift of the US healthcare system from volume- to value-based purchasing and the growing demand for quality patient care.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.